| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
159-217 |
DRI_Challenge |
denotes |
an assess tissue viability in acute ischemic stroke (AIS). |
| T2 |
218-333 |
DRI_Background |
denotes |
[18F]FMISO is an established tracer but requires substantial accumulation time, limiting its use in hyperacute AIS. |
| T3 |
334-421 |
DRI_Background |
denotes |
[64Cu]CuATSM requires less accumulation time and has shown promise as a hypoxia tracer. |
| T4 |
422-517 |
DRI_Approach |
denotes |
We compared these tracers in a M2-occlusion model (M2CAO) with preserved collateral blood flow. |
| T5 |
518-600 |
DRI_Background |
denotes |
Rats underwent M2CAO and [18F]FMISO (n = 12) or [64Cu]CuATSM (n = 6) examinations. |
| T6 |
601-650 |
DRI_Background |
denotes |
[64Cu]CuATSM animals were also examined with MRI. |
| T7 |
651-815 |
DRI_Background |
denotes |
Pimonidazole was used as a surrogate for [18F]FMISO in an immunofluorescence analysis employed to profile levels of hypoxia in neurons (NeuN) and astrocytes (GFAP). |
| T8 |
816-874 |
DRI_Background |
denotes |
There was increased [18F]FMISO uptake in the M2CAO cortex. |
| T9 |
923-1009 |
DRI_Background |
denotes |
The pimonidazole intensity of neurons and astrocytes was increased in hypoxic regions. |
| T10 |
1010-1084 |
DRI_Approach |
denotes |
The pimonidazole intensity ratio was higher in neurons than in astrocytes. |
| T11 |
1085-1224 |
DRI_Challenge |
denotes |
In the majority of animals, immunofluorescence revealed a loss of astrocytes within the core of regions with increased pimonidazole uptake. |
| T12 |
1225-1343 |
DRI_Approach |
denotes |
We conclude that [18F]FMISO is superior to [64Cu]CuATSM in detecting hypoxia in AIS, consistent with an earlier study. |
| T13 |
1344-1424 |
DRI_Outcome |
denotes |
[18F]FMISO may provide efficient diagnostic imaging beyond the hyperacute phase. |
| T14 |
1425-1510 |
DRI_Outcome |
denotes |
Results do not provide encouragement for the use of [64Cu]CuATSM in experimental AIS. |
